Pharming Group N.V annual shareholders’ equity
2018
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Shareholders’ Equity Growth & History (PHAR)
Pharming Group N.V's shareholders’ equity was $277.1M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $277.1M | $56.0M | +25.35% |
| 2024 | 2024-12-31 | $221.1M | $2.3M | +1.04% |
| 2023 | 2023-12-31 | $218.8M | $14.1M | +6.91% |
| 2022 | 2022-12-31 | $204.6M | $11.7M | +6.08% |
| 2021 | 2021-12-31 | $192.9M | $9.5M | +5.17% |
| 2020 | 2020-12-31 | $183.4M | $66.0M | +56.26% |
| 2019 | 2019-12-31 | $117.4M | $53.3M | +83.13% |
| 2018 | 2018-12-31 | $64.1M | — | — |
Pharming Group N.V quarterly shareholders’ equity
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $270.5M | $30.9M | +12.92% |
| Q1 2026 | 2026-03-31 | $269.0M | — | — |
| Q4 2025 | 2025-12-31 | $277.1M | $56.0M | +25.35% |
| Q3 2025 | 2025-09-30 | $264.6M | — | — |
| Q2 2025 | 2025-06-30 | $239.6M | — | — |
| Q4 2024 | 2024-12-31 | $221.1M | $2.3M | +1.04% |
| Q4 2023 | 2023-12-31 | $218.8M | $14.1M | +6.91% |
| Q4 2022 | 2022-12-31 | $204.6M | $11.7M | +6.08% |
| Q4 2021 | 2021-12-31 | $192.9M | — | — |
Pharming Group N.V shareholders’ equity trends
Over the last five fiscal years, Pharming Group N.V's shareholders’ equity increased from $183.4M to $277.1M, a change of $93.7M. The latest reported quarter, Q2 2026, shows $270.5M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...